


OCTAVO

StereOtaCTic AblatiVe radiotherapy for Oligometastatic disease following initial systemic therapy

Eric Hau

Background-Oligometastatic state



Current Ongoing Studies


<u>SART before systemic therapy</u>	<u>Systemic therapy before consolidation SART</u>	<u>Systemic therapy until progression, then SART</u>	<u>Site decision: SART before or after 3 months systemic therapy</u>	<u>Timing Not Specified</u>
PEMBRO-RT ²³	NRG LU002 (NCT03137771)	CURB ²⁴	OMEGA (NCT03827577)	SABR COMET 3 ²⁵
CORE (NCT02759783)	LONESTAR (NCT03391869)	HALT (NCT03256981)		SABR COMET 10 ²⁶
	SARON ²⁷	STOP (NCT02756793)		
	BLAD-RAD01 (NCT04428554)			

Study

- Timing of SART
- Multi-centre seamless phase 2/3, open label, randomised adaptive controlled trial
- 95 patients randomised 2:1

Study Schema


Figure 1: OCTAVO trial schema for the phase 2 component



NSCLC: Non-Small Cell Lung Cancer; R: Randomise; SART: stereotactic ablative radiotherapy.

Recruitment Workflow

Figure 2. Recruitment workflow



Endpoints

- **Phase 2 primary endpoint-** progression-free survival assessed at a landmark analysis 9 months after randomisation
- Secondary Endpoints: overall survival, local control of treated lesions, patterns of failure, PFS2 (2nd progression free survival), feasibility of treatment delivery, adverse events (according to Common Terminology Criteria for Adverse Events v5.0), time until change in therapy
- EORTC QLQ-C30
- Fear of cancer recurrence (FCR)
- Feasibility of collecting healthcare use data from trial records and linked Medicare (MBS/PBS)

Tertiary Endpoints

- Research blood from all participants at baseline;
- Consent from all participants for banking of archival tumour tissue
- CT scan data for radiomics analysis

Acknowledgements

- Martin Stocker
- Chee Lee
- Mark Pinkham
- Amy Hayden
- Sashendra Senth
- Rashed Mahumud
- Val Gebski
- Sonia Yip
- Rebecca Mercieca-Bebber
- Susan McCullough
- Michelle Cummins
- GCCTI
- NHMRC CTC
- TOGA
- MASC
- ANZUP
- TROG